Exact Mass: 469.1880568
Exact Mass Matches: 469.1880568
Found 500 metabolites which its exact mass value is equals to given mass value 469.1880568,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Nefazodone
Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury, which could lead to the need for a liver transplant, or even death. The incidence of severe liver damage is approximately 1 in 250,000 to 300,000 patient-years. On May 20, 2004, Bristol-Myers Squibb discontinued the sale of Serzone in the United States. [Wikipedia] D018377 - Neurotransmitter Agents > D014179 - Neurotransmitter Uptake Inhibitors > D000068760 - Serotonin and Noradrenaline Reuptake Inhibitors D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent N - Nervous system > N06 - Psychoanaleptics > N06A - Antidepressants D049990 - Membrane Transport Modulators Nefazodone is an orally active phenylpiperazine antidepressant. Nefazodone can potently and selectively block postsynaptic 5-HT2A receptors, and moderately inhibit 5-HT and noradrenaline reuptake. Nefazodone can also relieve the adverse effects of stress on the the immune system of mice. Nefazodone has a high affinity for CYP3A4 isoenzyme, which indicates that it has certain risk of agent-agent interaction. Nefazodone. CAS Common Chemistry. CAS, a division of the American Chemical Society, n.d. https://commonchemistry.cas.org/detail?cas_rn=83366-66-9 (retrieved 2024-10-16) (CAS RN: 83366-66-9). Licensed under the Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0).
Indol-3-ylacetyl-myo-inositol L-arabinoside
C21H27NO11 (469.15840320000007)
20-COOH-leukotriene E4
C23H35NO7S (469.21341200000006)
20-COOH-leukotriene E4 is a metabolite through lipid oxidation of Leukotriene E4 (LTE4).Leukotriene E4 (LTE4) is a cysteinyl leukotriene. Cysteinyl leukotrienes (CysLTs) are a family of potent inflammatory mediators that appear to contribute to the pathophysiologic features of allergic rhinitis. Nasal blockage induced by CysLTs is mainly due to dilatation of nasal blood vessels, which can be induced by the nitric oxide produced through CysLT1 receptor activation. LTE4, activate contractile and inflammatory processes via specific interaction with putative seven transmembrane-spanning receptors that couple to G proteins and subsequent intracellular signaling pathways. LTE4 is metabolized from leukotriene C4 in a reaction catalyzed by gamma-glutamyl transpeptidase and a particulate dipeptidase from kidney. (PMID: 12607939, 12432945, 6311078). Leukotrienes are eicosanoids. The eicosanoids consist of the prostaglandins (PGs), thromboxanes (TXs), leukotrienes (LTs), and lipoxins (LXs). The PGs and TXs are collectively identified as prostanoids. Prostaglandins were originally shown to be synthesized in the prostate gland, thromboxanes from platelets (thrombocytes), and leukotrienes from leukocytes, hence the derivation of their names. All mammalian cells except erythrocytes synthesize eicosanoids. These molecules are extremely potent, able to cause profound physiological effects at very dilute concentrations. All eicosanoids function locally at the site of synthesis, through receptor-mediated G-protein linked signalling pathways. 20-COOH-leukotriene E4 is a metabolite through lipid oxidation of Leukotriene E4 (LTE4).Leukotriene E4 (LTE4) is a cysteinyl leukotriene. Cysteinyl leukotrienes (CysLTs) are a family of potent inflammatory mediators that appear to contribute to the pathophysiologic features of allergic rhinitis. Nasal blockage induced by CysLTs is mainly due to dilatation of nasal blood vessels, which can be induced by the nitric oxide produced through CysLT1 receptor activation. LTE4, activate contractile and inflammatory processes via specific interaction with putative seven transmembrane-spanning receptors that couple to G proteins and subsequent intracellular signaling pathways. LTE4 is metabolized from leukotriene C4 in a reaction catalyzed by gamma-glutamyl transpeptidase and a particulate dipeptidase from kidney. (PMID: 12607939, 12432945, 6311078)
Dactolisib
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C2152 - Phosphatidylinositide 3-Kinase Inhibitor C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor D000970 - Antineoplastic Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
N-(2-(3-(Piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl)phenyl)quinoxaline-2-carboxamide
SRT 1720 is a selective activator of human SIRT1 with an EC1.5 of 0.16 μM, and shows less potent activities for SIRT2 and SIRT3 with EC1.5s of 37 μM and > 300 μM, respectively.
2-Methoxy-N-[3-[4-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]anilino]-6-quinazolinyl]prop-2-enyl]acetamide
Dacomitinib
Ethanol and folate
H-Asp-ala-his-lys-OH
5-O-beta-D-Glucopyranosyldihydroascorbigen
C21H27NO11 (469.15840320000007)
2-[1-[4,5-dihydroxy-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]indol-3-yl]acetic acid
C21H27NO11 (469.15840320000007)
latrunculol B
C23H35NO7S (469.21341200000006)
A natural product found in Cacospongia mycofijiensis.
5-O-beta-D-glucopyranosyl-dihydroABG|5-O-beta-D-glucopyranosyl-dihydroascorbigen
C21H27NO11 (469.15840320000007)
His Asn Ala Glu
C18H27N7O8 (469.19210219999997)
Ala Lys His Asp
SRT 1720
SRT 1720 is a selective activator of human SIRT1 with an EC1.5 of 0.16 μM, and shows less potent activities for SIRT2 and SIRT3 with EC1.5s of 37 μM and > 300 μM, respectively.
CAY10589
C25H28ClN3O2S (469.15906580000006)
Asn Ala His Glu
C18H27N7O8 (469.19210219999997)
Gln Ala His Asp
C18H27N7O8 (469.19210219999997)
(indol-3-yl)acetyl-myo-inositol L-arabinoside
C21H27NO11 (469.15840320000007)
C24H27N3O7_Prolinamide, N-(4-hydroxybenzoyl)valyl-N-(2-carboxy-6-hydroxyphenyl)
C24H27N3O7 (469.18489120000004)
nefazodone
D018377 - Neurotransmitter Agents > D014179 - Neurotransmitter Uptake Inhibitors > D000068760 - Serotonin and Noradrenaline Reuptake Inhibitors D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent N - Nervous system > N06 - Psychoanaleptics > N06A - Antidepressants D049990 - Membrane Transport Modulators Nefazodone is an orally active phenylpiperazine antidepressant. Nefazodone can potently and selectively block postsynaptic 5-HT2A receptors, and moderately inhibit 5-HT and noradrenaline reuptake. Nefazodone can also relieve the adverse effects of stress on the the immune system of mice. Nefazodone has a high affinity for CYP3A4 isoenzyme, which indicates that it has certain risk of agent-agent interaction[1][2][3].
3-hydroxy-2-[[1-[2-[(4-hydroxybenzoyl)amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]benzoic acid
C24H27N3O7 (469.18489120000004)
Ala Cys Asn Tyr
Ala Cys Tyr Asn
Ala Asp His Lys
Ala Asp His Gln
C18H27N7O8 (469.19210219999997)
Ala Asp Lys His
Ala Asp Gln His
C18H27N7O8 (469.19210219999997)
Ala Glu His Asn
C18H27N7O8 (469.19210219999997)
Ala Glu Asn His
C18H27N7O8 (469.19210219999997)
Ala Gly His Trp
C22H27N7O5 (469.20735720000005)
Ala Gly Trp His
C22H27N7O5 (469.20735720000005)
Ala His Asp Lys
Ala His Asp Gln
C18H27N7O8 (469.19210219999997)
Ala His Glu Asn
C18H27N7O8 (469.19210219999997)
Ala His Gly Trp
C22H27N7O5 (469.20735720000005)
Ala His Lys Asp
Ala His Asn Glu
C18H27N7O8 (469.19210219999997)
Ala His Gln Asp
C18H27N7O8 (469.19210219999997)
Ala His Trp Gly
C22H27N7O5 (469.20735720000005)
Ala Lys Asp His
Ala Asn Cys Tyr
Ala Asn Glu His
C18H27N7O8 (469.19210219999997)
Ala Asn His Glu
C18H27N7O8 (469.19210219999997)
Ala Asn Tyr Cys
Ala Gln Asp His
C18H27N7O8 (469.19210219999997)
Ala Gln His Asp
C18H27N7O8 (469.19210219999997)
Ala Trp Gly His
C22H27N7O5 (469.20735720000005)
Ala Trp His Gly
C22H27N7O5 (469.20735720000005)
Ala Tyr Cys Asn
Ala Tyr Asn Cys
Cys Ala Asn Tyr
Cys Ala Tyr Asn
Cys Phe Asn Ser
Cys Phe Ser Asn
Cys Gly Lys Tyr
C20H31N5O6S (469.19949460000004)
Cys Gly Gln Tyr
Cys Gly Tyr Lys
C20H31N5O6S (469.19949460000004)
Cys Gly Tyr Gln
Cys His Asn Pro
Cys His Pro Asn
Cys Lys Gly Tyr
C20H31N5O6S (469.19949460000004)
Cys Lys Tyr Gly
C20H31N5O6S (469.19949460000004)
Cys Asn Ala Tyr
Cys Asn Phe Ser
Cys Asn His Pro
Cys Asn Pro His
Cys Asn Ser Phe
Cys Asn Tyr Ala
Cys Pro His Asn
Cys Pro Asn His
Cys Gln Gly Tyr
Cys Gln Tyr Gly
Cys Ser Phe Asn
Cys Ser Asn Phe
Cys Tyr Ala Asn
Cys Tyr Gly Lys
C20H31N5O6S (469.19949460000004)
Cys Tyr Gly Gln
Cys Tyr Lys Gly
C20H31N5O6S (469.19949460000004)
Cys Tyr Asn Ala
Cys Tyr Gln Gly
Asp Ala His Lys
Asp Ala His Gln
C18H27N7O8 (469.19210219999997)
Asp Ala Lys His
Asp Ala Gln His
C18H27N7O8 (469.19210219999997)
Asp His Ala Lys
Asp His Ala Gln
C18H27N7O8 (469.19210219999997)
Asp His Lys Ala
Asp His Gln Ala
C18H27N7O8 (469.19210219999997)
Asp Lys Ala His
Asp Lys His Ala
Asp Gln Ala His
C18H27N7O8 (469.19210219999997)
Asp Gln His Ala
C18H27N7O8 (469.19210219999997)
Glu Ala His Asn
C18H27N7O8 (469.19210219999997)
Glu Ala Asn His
C18H27N7O8 (469.19210219999997)
Glu Gly His Lys
Glu Gly His Gln
C18H27N7O8 (469.19210219999997)
Glu Gly Lys His
Glu Gly Gln His
C18H27N7O8 (469.19210219999997)
Glu His Ala Asn
C18H27N7O8 (469.19210219999997)
Glu His Gly Lys
Glu His Gly Gln
C18H27N7O8 (469.19210219999997)
Glu His Lys Gly
Glu His Asn Ala
C18H27N7O8 (469.19210219999997)
Glu His Gln Gly
C18H27N7O8 (469.19210219999997)
Glu Lys Gly His
Glu Lys His Gly
Glu Asn Ala His
C18H27N7O8 (469.19210219999997)
Glu Asn His Ala
C18H27N7O8 (469.19210219999997)
Glu Pro Pro Gln
Glu Pro Gln Pro
Glu Gln Gly His
C18H27N7O8 (469.19210219999997)
Glu Gln His Gly
C18H27N7O8 (469.19210219999997)
Glu Gln Pro Pro
Phe Cys Asn Ser
Phe Cys Ser Asn
Phe Asn Cys Ser
Phe Asn Ser Cys
Phe Ser Cys Asn
Phe Ser Asn Cys
Gly Ala His Trp
C22H27N7O5 (469.20735720000005)
Gly Ala Trp His
C22H27N7O5 (469.20735720000005)
Gly Cys Lys Tyr
C20H31N5O6S (469.19949460000004)
Gly Cys Gln Tyr
Gly Cys Tyr Lys
C20H31N5O6S (469.19949460000004)
Gly Cys Tyr Gln
Gly Glu His Lys
Gly Glu His Gln
C18H27N7O8 (469.19210219999997)
Gly Glu Lys His
Gly Glu Gln His
C18H27N7O8 (469.19210219999997)
Gly His Ala Trp
C22H27N7O5 (469.20735720000005)
Gly His Glu Lys
Gly His Glu Gln
C18H27N7O8 (469.19210219999997)
Gly His Lys Glu
Gly His Gln Glu
C18H27N7O8 (469.19210219999997)
Gly His Trp Ala
C22H27N7O5 (469.20735720000005)
Gly Lys Cys Tyr
C20H31N5O6S (469.19949460000004)
Gly Lys Glu His
Gly Lys His Glu
Gly Lys Tyr Cys
C20H31N5O6S (469.19949460000004)
Gly Gln Cys Tyr
Gly Gln Glu His
C18H27N7O8 (469.19210219999997)
Gly Gln His Glu
C18H27N7O8 (469.19210219999997)
Gly Gln Tyr Cys
Gly Trp Ala His
C22H27N7O5 (469.20735720000005)
Gly Trp His Ala
C22H27N7O5 (469.20735720000005)
Gly Tyr Cys Lys
C20H31N5O6S (469.19949460000004)
Gly Tyr Cys Gln
Gly Tyr Lys Cys
C20H31N5O6S (469.19949460000004)
Gly Tyr Gln Cys
His Ala Asp Lys
His Ala Asp Gln
C18H27N7O8 (469.19210219999997)
His Ala Glu Asn
C18H27N7O8 (469.19210219999997)
His Ala Gly Trp
C22H27N7O5 (469.20735720000005)
His Ala Lys Asp
His Ala Asn Glu
C18H27N7O8 (469.19210219999997)
His Ala Gln Asp
C18H27N7O8 (469.19210219999997)
His Ala Trp Gly
C22H27N7O5 (469.20735720000005)
His Cys Asn Pro
His Cys Pro Asn
His Asp Ala Lys
His Asp Ala Gln
C18H27N7O8 (469.19210219999997)
His Asp Lys Ala
His Asp Gln Ala
C18H27N7O8 (469.19210219999997)
His Glu Ala Asn
C18H27N7O8 (469.19210219999997)
His Glu Gly Lys
His Glu Gly Gln
C18H27N7O8 (469.19210219999997)
His Glu Lys Gly
His Glu Asn Ala
C18H27N7O8 (469.19210219999997)
His Glu Gln Gly
C18H27N7O8 (469.19210219999997)
His Gly Ala Trp
C22H27N7O5 (469.20735720000005)
His Gly Glu Lys
His Gly Glu Gln
C18H27N7O8 (469.19210219999997)
His Gly Lys Glu
His Gly Gln Glu
C18H27N7O8 (469.19210219999997)
His Gly Trp Ala
C22H27N7O5 (469.20735720000005)
His Ile Asn Ser
His Ile Ser Asn
His Lys Ala Asp
His Lys Asp Ala
His Lys Glu Gly
His Lys Gly Glu
His Leu Asn Ser
His Leu Ser Asn
His Asn Cys Pro
His Asn Glu Ala
C18H27N7O8 (469.19210219999997)
His Asn Ile Ser
His Asn Leu Ser
His Asn Pro Cys
His Asn Ser Ile
His Asn Ser Leu
His Asn Thr Val
His Pro Cys Asn
His Pro Asn Cys
His Gln Ala Asp
C18H27N7O8 (469.19210219999997)
His Gln Asp Ala
C18H27N7O8 (469.19210219999997)
His Gln Glu Gly
C18H27N7O8 (469.19210219999997)
His Gln Gly Glu
C18H27N7O8 (469.19210219999997)
His Trp Ala Gly
C22H27N7O5 (469.20735720000005)
His Trp Gly Ala
C22H27N7O5 (469.20735720000005)
Lys Cys Gly Tyr
C20H31N5O6S (469.19949460000004)
Lys Cys Tyr Gly
C20H31N5O6S (469.19949460000004)
Lys Gly Cys Tyr
C20H31N5O6S (469.19949460000004)
Lys Gly Tyr Cys
C20H31N5O6S (469.19949460000004)
Lys Tyr Cys Gly
C20H31N5O6S (469.19949460000004)
Lys Tyr Gly Cys
C20H31N5O6S (469.19949460000004)
Asn Ala Cys Tyr
Asn Ala Glu His
C18H27N7O8 (469.19210219999997)
Asn Ala Tyr Cys
Asn Cys Ala Tyr
Asn Cys Phe Ser
Asn Cys His Pro
Asn Cys Pro His
Asn Cys Ser Phe
Asn Cys Tyr Ala
Asn Glu Ala His
C18H27N7O8 (469.19210219999997)
Asn Glu His Ala
C18H27N7O8 (469.19210219999997)
Asn Phe Cys Ser
Asn Phe Ser Cys
Asn His Ala Glu
C18H27N7O8 (469.19210219999997)
Asn His Cys Pro
Asn His Glu Ala
C18H27N7O8 (469.19210219999997)
Asn His Pro Cys
Asn Pro Cys His
Asn Pro His Cys
Asn Ser Cys Phe
Asn Ser Phe Cys
Asn Ser Ser Tyr
C19H27N5O9 (469.18086919999996)
Asn Ser Tyr Ser
C19H27N5O9 (469.18086919999996)
Asn Tyr Ala Cys
Asn Tyr Cys Ala
Asn Tyr Ser Ser
C19H27N5O9 (469.18086919999996)
Pro Cys His Asn
Pro Cys Asn His
Pro Glu Pro Gln
Pro Glu Gln Pro
Pro His Cys Asn
Pro His Asn Cys
Pro Asn Cys His
Pro Asn His Cys
Pro Pro Glu Gln
Pro Pro Gln Glu
Pro Gln Glu Pro
Pro Gln Pro Glu
Gln Ala Asp His
C18H27N7O8 (469.19210219999997)
Gln Cys Gly Tyr
Gln Cys Tyr Gly
Gln Asp Ala His
C18H27N7O8 (469.19210219999997)
Gln Asp His Ala
C18H27N7O8 (469.19210219999997)
Gln Glu Gly His
C18H27N7O8 (469.19210219999997)
Gln Glu His Gly
C18H27N7O8 (469.19210219999997)
Gln Glu Pro Pro
Gln Gly Cys Tyr
Gln Gly Glu His
C18H27N7O8 (469.19210219999997)
Gln Gly His Glu
C18H27N7O8 (469.19210219999997)
Gln Gly Tyr Cys
Gln His Ala Asp
C18H27N7O8 (469.19210219999997)
Gln His Asp Ala
C18H27N7O8 (469.19210219999997)
Gln His Glu Gly
C18H27N7O8 (469.19210219999997)
Gln His Gly Glu
C18H27N7O8 (469.19210219999997)
Gln Pro Glu Pro
Gln Pro Pro Glu
Gln Tyr Cys Gly
Gln Tyr Gly Cys
Ser Cys Phe Asn
Ser Cys Asn Phe
Ser Phe Cys Asn
Ser Phe Asn Cys
Ser Asn Cys Phe
Ser Asn Phe Cys
Ser Asn Ser Tyr
C19H27N5O9 (469.18086919999996)
Ser Asn Tyr Ser
C19H27N5O9 (469.18086919999996)
Ser Ser Asn Tyr
C19H27N5O9 (469.18086919999996)
Ser Ser Tyr Asn
C19H27N5O9 (469.18086919999996)
Ser Tyr Asn Ser
C19H27N5O9 (469.18086919999996)
Ser Tyr Ser Asn
C19H27N5O9 (469.18086919999996)
Trp Ala Gly His
C22H27N7O5 (469.20735720000005)
Trp Ala His Gly
C22H27N7O5 (469.20735720000005)
Trp Gly Ala His
C22H27N7O5 (469.20735720000005)
Trp Gly His Ala
C22H27N7O5 (469.20735720000005)
Trp His Ala Gly
C22H27N7O5 (469.20735720000005)
Trp His Gly Ala
C22H27N7O5 (469.20735720000005)
Tyr Ala Cys Asn
Tyr Ala Asn Cys
Tyr Cys Ala Asn
Tyr Cys Gly Lys
C20H31N5O6S (469.19949460000004)
Tyr Cys Gly Gln
Tyr Cys Lys Gly
C20H31N5O6S (469.19949460000004)
Tyr Cys Asn Ala
Tyr Cys Gln Gly
Tyr Gly Cys Lys
C20H31N5O6S (469.19949460000004)
Tyr Gly Cys Gln
Tyr Gly Lys Cys
C20H31N5O6S (469.19949460000004)
Tyr Gly Gln Cys
Tyr Lys Cys Gly
C20H31N5O6S (469.19949460000004)
Tyr Lys Gly Cys
C20H31N5O6S (469.19949460000004)
Tyr Asn Ala Cys
Tyr Asn Cys Ala
Tyr Asn Ser Ser
C19H27N5O9 (469.18086919999996)
Tyr Gln Cys Gly
Tyr Gln Gly Cys
Tyr Ser Asn Ser
C19H27N5O9 (469.18086919999996)
Tyr Ser Ser Asn
C19H27N5O9 (469.18086919999996)
NVP-BEZ235
N-(4-Hydroxybenzoyl)valyl-N-(2-carboxy-6-hydroxyphenyl)prolinamide
C24H27N3O7 (469.18489120000004)
20-COOH-leukotriene E4
C23H35NO7S (469.21341200000006)
20-carboxy-LTE4
C23H35NO7S (469.21341200000006)
Belotecan hydrochloride
C25H28ClN3O4 (469.1768238000001)
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor D000970 - Antineoplastic Agents > D059003 - Topoisomerase Inhibitors > D059004 - Topoisomerase I Inhibitors C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C1748 - Topoisomerase Inhibitor D004791 - Enzyme Inhibitors
1-[2-[[4-[(2-chloro-4-nitrophenyl)azo]phenyl]ethylamino]ethyl]pyridinium acetate
C23H24ClN5O4 (469.15167340000005)
Dacomitinib
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EB - Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
fmoc-(s)-3-amino-4-(2-trifluoromethyl-phenyl)-butyric acid
C26H22F3NO4 (469.15008480000006)
BENZENE, 1,1-[(4-NITROPHENYL)METHYLENE]BIS[2,4,6-TRIMETHOXY]-
C25H27NO8 (469.17365820000003)
CP-724714
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163760 - HER2-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C159156 - HER2 Inhibitor
2-Nitrophenyl2,3-di-O-acetyl-4-O-triethylsilyl-b-D-xylopyranoside
C21H31NO9Si (469.17679960000004)
Fmoc-(S)-3-Amino-4-(4-trifluoromethylphenyl)-butyric acid
C26H22F3NO4 (469.15008480000006)
dimenhydrinate
R - Respiratory system > R06 - Antihistamines for systemic use > R06A - Antihistamines for systemic use > R06AA - Aminoalkyl ethers C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents C78272 - Agent Affecting Nervous System > C267 - Antiemetic Agent D005765 - Gastrointestinal Agents > D000932 - Antiemetics D002491 - Central Nervous System Agents Dimenhydrinate is an orally active H1-antihistamine consisting of Diphenhydramine (HY-B0303) and 8-Chlorotheophylline. Dimenhydrinate is used to prevent nausea, vomiting, dizziness, and vertigo associated with motion sickness[1].
Fmoc-(R)-3-Amino-4-(2-trifluoromethylphenyl)-butyric acid
C26H22F3NO4 (469.15008480000006)
Fmoc-(R)-3-Amino-4-(4-trifluoromethyl-phenyl)-butyric acid
C26H22F3NO4 (469.15008480000006)
Fmoc-(S)-3-Amino-4-(3-trifluoromethylphenyl)-butyric acid
C26H22F3NO4 (469.15008480000006)
Almotriptan
C21H31N3O7S (469.18826160000003)
D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists C78272 - Agent Affecting Nervous System > C47794 - Serotonin Agonist Almotriptan Malate is a 5-HT1B/1D-receptor agonist used to treat migraine. IC50: Target: 5-hydroxytryptamine1B/1D (5-HT1B/1D) Receptor Almotriptan Malate is a selective 5-hydroxytryptamine1B/1D (5-HT1B/1D) receptor agonist, used for the treatment of Migraine attacks in adults. Almotriptan showed low nanomolar affinity for the 5-HT(1B) and 5-HT(1D) receptors in several species, including the human, while affinity for 5-HT receptors other than 5-HT(1B/1D) was clearly less. Almotriptan did not exhibit significant affinity for several non-5-HT receptors studied up to 100 microM. Almotriptan inhibited forskolin-stimulated cyclic AMP accumulation in HeLa cells transfected with 5-HT(1B) or 5-HT(1D) human receptors [1]. Almotriptan had a mild antiemetic effect and a slight, transient diuretic effect in dogs, although the latter effect is probably of no clinical relevance. In addition, no effect on the respiratory system of conscious guinea pigs was observed following almotriptan treatment. These results indicate that almotriptan has a favourable safety profile with respect to the central nervous, renal and respiratory systems [2].
benzylpenicillin β-diethylaminoethyl ester hydrochloride
C22H32ClN3O4S (469.1801942000001)
methysergide
D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists D002317 - Cardiovascular Agents > D014662 - Vasoconstrictor Agents C78272 - Agent Affecting Nervous System > C47795 - CNS Stimulant
Gandotinib
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
5-TBDMS-Bz-dA
5'-O-TBDMS-Bz-dA is a nucleoside with protective and modification effects.
Fmoc-(R)-3-Amino-4-(3-trifluoromethylphenyl)-butyric acid
C26H22F3NO4 (469.15008480000006)
D-Glucopyranose, 2-azido-2-deoxy-3,4-bis-O-(phenylMethyl)-, 1,6-diacetate
C24H27N3O7 (469.18489120000004)
(E)-N-(4-(3-(tert-Butyl)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxystyryl)phenyl)methanesulfonamide
C24H27N3O5S (469.1671332000001)
4H-1,2,4-Triazole, 3-(4-(3-(ethylsulfonyl)propyl)bicyclo(2.2.2)oct-1-yl)-4-methyl-5-(2-(trifluoromethyl)phenyl)-
C23H30F3N3O2S (469.20107160000003)
Mycophenolate mofetil hydrochloride
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D000995 - Antitubercular Agents C471 - Enzyme Inhibitor > C2087 - Inosine Monophosphate Dehydrogenase Inhibitor C308 - Immunotherapeutic Agent > C574 - Immunosuppressant D000970 - Antineoplastic Agents D004791 - Enzyme Inhibitors
CID 54733074
(4as,4br,10bs,12as)-12a-Methyl-1,3-Dioxo-2-(Pyridin-3-Ylmethyl)-1,2,3,4,4a,4b,5,6,10b,11,12,12a-Dodecahydronaphtho[2,1-F]isoquinolin-8-Yl Sulfamate
C24H27N3O5S (469.1671332000001)
(2S)-6-(2,4-diamino-6-ethylpyrimidin-5-yl)-2-(3,5-difluorophenyl)-4-(3-methoxypropyl)-1,4-benzoxazin-3-one
Dactolisib
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C2152 - Phosphatidylinositide 3-Kinase Inhibitor C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor D000970 - Antineoplastic Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
2-[(4-{[([1,1-Biphenyl]-4-yl)methyl]amino}-6-chloropyrimidin-2-yl)sulfanyl]octanoic acid
C25H28ClN3O2S (469.15906580000006)
(6Z,9Z,11E,13E,15R,16S)-15-{[(2R)-2-amino-2-carboxyethyl]sulfanyl}-16-hydroxyicosa-6,9,11,13-tetraenedioic acid
C23H35NO7S (469.21341200000006)
(2R,3R,4S,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2S,3R,4R,5S,6R)-3-amino-4,5-dihydroxy-6-(1-hydroxyethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxyoxane-3,4,5-triol
C18H35N3O11 (469.22714800000006)
(2S)-2-[[[4-[(2-amino-4-oxo-3H-quinazolin-6-yl)methyl-formylamino]phenyl]-hydroxymethyl]amino]pentanedioic acid
2-(4-Nitrophenoxy)-1-[4-(4-phenylphthalazin-1-yl)piperazin-1-yl]ethanone
C26H23N5O4 (469.17499580000003)
(indol-3-ylacetyl)-myo-inositol 3-L-arabinoside
C21H27NO11 (469.15840320000007)
[5-(4-Fluorophenyl)-7-(trifluoromethyl)-2-pyrazolo[1,5-a]pyrimidinyl]-[2-(3-pyridinyl)-1-piperidinyl]methanone
1-(1-tert-butyl-5-tetrazolyl)-N-(2-furanylmethyl)-N-(phenylmethyl)-1-[4-(trifluoromethyl)phenyl]methanamine
C25H26F3N5O (469.20893420000004)
3-methyl-2-[(4-methylphenyl)sulfonylamino]pentanoic acid (4-oxo-2,3-dihydro-1H-cyclopenta[c][1]benzopyran-7-yl) ester
C25H27NO6S (469.1559002000001)
(4-oxo-2,3-dihydro-1H-cyclopenta[c]chromen-7-yl) 4-methyl-2-[(4-methylphenyl)sulfonylamino]pentanoate
C25H27NO6S (469.1559002000001)
4-[3-oxo-1-(3,4,5-trimethoxyanilino)-1H-isoindol-2-yl]-1-piperidinecarboxylic acid ethyl ester
3-{[4-(4-methoxyphenyl)piperazin-1-yl]carbonyl}benzimidazo[1,2-c]quinazoline-6(5H)-thione
2-{2-oxo-2-[4-(2,3,4-trimethoxybenzyl)piperazin-1-yl]ethyl}-3a,4,7,7a-tetrahydro-1H-4,7-methanoisoindole-1,3-dione
1,3-bis(2-deoxy-beta-D-erythro-pentofuranosyl)-5-amino-5-methyl-6-{2-oxo-1,3-diazabicyclo[2.2.0]hex-4-en-6-yl}-1,3-diazinane-2,4-dione
C19H27N5O9 (469.18086919999996)
An N-glycosyl compound that is a metabolite produced by the bacterium Mycoplasma genitalium.
6-amino-1,3-bis(2-deoxy-beta-D-erythro-pentofuranosyl)-5-hydroxy-5-methyl-3,4-dihydro[4,4-bipyrimidine]-2,2(1H,3H)-dione
C19H27N5O9 (469.18086919999996)
An N-glycosyl compound that is a metabolite produced by the bacterium Mycoplasma genitalium.
dihydroascorbigen 5-O-beta-D-glucoside
C21H27NO11 (469.15840320000007)
A dihydroascorbigen hexoside in which the hexoside component is a beta-D-glucosyl residue attached at position 5 via a glycosidic bond.
2-[(2R,4aR,12aR)-8-(ethylsulfonylamino)-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-(2-methoxyethyl)acetamide
C21H31N3O7S (469.18826160000003)
1-[(2R,3R,6R)-6-[2-(4-benzyltriazol-1-yl)ethyl]-2-(hydroxymethyl)oxan-3-yl]-3-(3-chlorophenyl)urea
2-[(2S,4aR,12aR)-8-(ethylsulfonylamino)-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-(2-methoxyethyl)acetamide
C21H31N3O7S (469.18826160000003)
N-[(2R,4aS,12aR)-2-[2-(dimethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-4-fluorobenzamide
C25H28FN3O5 (469.20128900000003)
N-[(2S,4aR,12aS)-2-[2-(dimethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-4-fluorobenzamide
C25H28FN3O5 (469.20128900000003)
(1S,9R,10R,11R)-5-(cyclohexen-1-yl)-N-[(3,5-difluorophenyl)methyl]-10-(hydroxymethyl)-12-methyl-6-oxo-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
1-[(2S,3R,6S)-6-[2-(4-benzyltriazol-1-yl)ethyl]-2-(hydroxymethyl)oxan-3-yl]-3-(3-chlorophenyl)urea
1-[(2R,3S,6R)-6-[2-(4-benzyltriazol-1-yl)ethyl]-2-(hydroxymethyl)oxan-3-yl]-3-(3-chlorophenyl)urea
2-[(2R,4aR,12aS)-8-(ethylsulfonylamino)-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-(2-methoxyethyl)acetamide
C21H31N3O7S (469.18826160000003)
N-[(2S,4aS,12aR)-2-[2-(dimethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-4-fluorobenzamide
C25H28FN3O5 (469.20128900000003)
N-[(2S,4aR,12aR)-2-[2-(dimethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-4-fluorobenzamide
C25H28FN3O5 (469.20128900000003)
N-[(2R,4aR,12aR)-2-[2-(dimethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-4-fluorobenzamide
C25H28FN3O5 (469.20128900000003)
N-[(2R,4aS,12aS)-2-[2-(dimethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-4-fluorobenzamide
C25H28FN3O5 (469.20128900000003)
N-[(4S,7S,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-1,3-benzodioxole-5-carboxamide
N-[(4R,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-1,3-benzodioxole-5-carboxamide
1-(3-chlorophenyl)-3-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-[4-(phenylmethyl)-1-triazolyl]ethyl]-3-oxanyl]urea
2-[(1R,3R,4aR,9aS)-6-[[(2-fluoroanilino)-oxomethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide
C25H28FN3O5 (469.20128900000003)
2-[(1R,3S,4aR,9aS)-6-[[(2-fluoroanilino)-oxomethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide
C25H28FN3O5 (469.20128900000003)
2-[(1R,3R,4aS,9aR)-6-[[(2-fluoroanilino)-oxomethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide
C25H28FN3O5 (469.20128900000003)
2-[(1S,3R,4aR,9aS)-6-[[(2-fluoroanilino)-oxomethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide
C25H28FN3O5 (469.20128900000003)
2-[(2S,4aS,12aR)-8-(ethylsulfonylamino)-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-(2-methoxyethyl)acetamide
C21H31N3O7S (469.18826160000003)
2-[(2S,4aS,12aS)-8-(ethylsulfonylamino)-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-(2-methoxyethyl)acetamide
C21H31N3O7S (469.18826160000003)
2-[(2R,4aS,12aS)-8-(ethylsulfonylamino)-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-(2-methoxyethyl)acetamide
C21H31N3O7S (469.18826160000003)
N-[(2S,4aS,12aS)-2-[2-(dimethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-4-fluorobenzamide
C25H28FN3O5 (469.20128900000003)
(3S)-2-tert-butylsulfinyl-4-[3-[3-(dimethylamino)prop-1-ynyl]phenyl]-3-(2-hydroxyethyl)-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxylic acid
C25H31N3O4S (469.20351660000006)
1-[(1S)-1-[(4-chlorophenyl)methyl]-1-(hydroxymethyl)-7-methoxy-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]-2-methoxyethanone
C25H28ClN3O4 (469.1768238000001)
[(1R)-7-methoxy-9-methyl-1-(3-methylphenyl)sulfonyl-1-spiro[2,3-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]methanol
C25H31N3O4S (469.20351660000006)
N-[(4S,7R,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-1,3-benzodioxole-5-carboxamide
N-[(4S,7R,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-1,3-benzodioxole-5-carboxamide
N-[(4S,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-1,3-benzodioxole-5-carboxamide
N-[(4R,7R,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-1,3-benzodioxole-5-carboxamide
N-[(4R,7S,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-1,3-benzodioxole-5-carboxamide
1-(3-chlorophenyl)-3-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-[4-(phenylmethyl)-1-triazolyl]ethyl]-3-oxanyl]urea
1-(3-chlorophenyl)-3-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-[4-(phenylmethyl)-1-triazolyl]ethyl]-3-oxanyl]urea
1-(3-chlorophenyl)-3-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-[4-(phenylmethyl)-1-triazolyl]ethyl]-3-oxanyl]urea
1-(3-chlorophenyl)-3-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-[4-(phenylmethyl)-1-triazolyl]ethyl]-3-oxanyl]urea
2-[(1S,3S,4aS,9aR)-6-[[(2-fluoroanilino)-oxomethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide
C25H28FN3O5 (469.20128900000003)
2-[(1S,3R,4aS,9aR)-6-[[(2-fluoroanilino)-oxomethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide
C25H28FN3O5 (469.20128900000003)
2-[(1S,3S,4aR,9aS)-6-[[(2-fluoroanilino)-oxomethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide
C25H28FN3O5 (469.20128900000003)
2-[(1R,3S,4aS,9aR)-6-[[(2-fluoroanilino)-oxomethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide
C25H28FN3O5 (469.20128900000003)
(3S)-4-[3-(1-cyclohexenyl)phenyl]-3-(2-hydroxyethyl)-N,N-dimethyl-2-methylsulfonyl-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide
C25H31N3O4S (469.20351660000006)
2-[(2R,4aS,12aR)-8-(ethylsulfonylamino)-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-(2-methoxyethyl)acetamide
C21H31N3O7S (469.18826160000003)
2-[(2S,4aR,12aS)-8-(ethylsulfonylamino)-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-(2-methoxyethyl)acetamide
C21H31N3O7S (469.18826160000003)
N-[(2R,4aR,12aS)-2-[2-(dimethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-4-fluorobenzamide
C25H28FN3O5 (469.20128900000003)
(1R,9S,10S,11S)-5-(cyclohexen-1-yl)-N-[(3,5-difluorophenyl)methyl]-10-(hydroxymethyl)-12-methyl-6-oxo-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
[(1S)-7-methoxy-2-methyl-1-(4-methylphenyl)sulfonyl-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]methanol
C25H31N3O4S (469.20351660000006)
[(1R)-7-methoxy-2-methyl-1-(4-methylphenyl)sulfonyl-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]methanol
C25H31N3O4S (469.20351660000006)
1-[(1R)-1-[(4-chlorophenyl)methyl]-1-(hydroxymethyl)-7-methoxy-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]-2-methoxyethanone
C25H28ClN3O4 (469.1768238000001)
1-[(1S)-2-[(3-chlorophenyl)methyl]-1-(hydroxymethyl)-7-methoxy-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]-2-methoxyethanone
C25H28ClN3O4 (469.1768238000001)
1-[(1R)-1-(benzenesulfonyl)-1-(hydroxymethyl)-7-methoxy-9-methyl-2-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]yl]ethanone
C24H27N3O5S (469.1671332000001)
2-(dimethylamino)-1-[(1R)-1-(hydroxymethyl)-7-methoxy-9-methyl-1-(2-thiazolylmethyl)-2-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]yl]ethanone
2-(dimethylamino)-1-[(1S)-1-(hydroxymethyl)-7-methoxy-9-methyl-1-(2-thiazolylmethyl)-2-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]yl]ethanone
[(1S)-7-methoxy-9-methyl-1-(3-methylphenyl)sulfonyl-1-spiro[2,3-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]methanol
C25H31N3O4S (469.20351660000006)
[(1S)-7-methoxy-9-methyl-1-(4-methylphenyl)sulfonyl-1-spiro[2,3-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]methanol
C25H31N3O4S (469.20351660000006)
6-amino-N-{4-[(3-chloro-4-fluorophenyl)amino]-3-cyano-7-ethoxyquinolin-6-yl}hexanamide
methyl (2S)-2-[[(2Z)-2-(3,5-dioxo-4-phenyloxolan-2-ylidene)-2-phenylacetyl]amino]-3-phenylpropanoate
2-amino-4-({1-[(carboxymethyl)-C-hydroxycarbonimidoyl]-2-{[2-(hydroxymethyl)-3-oxo-1-phenylpropyl]sulfanyl}ethyl}-C-hydroxycarbonimidoyl)butanoic acid
C20H27N3O8S (469.15187820000006)
2-amino-4-({1-[(carboxymethyl)-C-hydroxycarbonimidoyl]-2-{[1-(3-hydroxyphenyl)-2-methyl-3-oxopropyl]sulfanyl}ethyl}-C-hydroxycarbonimidoyl)butanoic acid
C20H27N3O8S (469.15187820000006)
2-amino-4-({1-[(carboxymethyl)-C-hydroxycarbonimidoyl]-2-[(2-hydroxy-3-oxo-1-phenylbutyl)sulfanyl]ethyl}-C-hydroxycarbonimidoyl)butanoic acid
C20H27N3O8S (469.15187820000006)
2-amino-4-({1-[(carboxymethyl)-C-hydroxycarbonimidoyl]-2-{[1-(4-hydroxyphenyl)-2-methyl-3-oxopropyl]sulfanyl}ethyl}-C-hydroxycarbonimidoyl)butanoic acid
C20H27N3O8S (469.15187820000006)
2-amino-4-({1-[(carboxymethyl)-C-hydroxycarbonimidoyl]-2-[(2-hydroxy-2-methyl-3-oxo-1-phenylpropyl)sulfanyl]ethyl}-C-hydroxycarbonimidoyl)butanoic acid
C20H27N3O8S (469.15187820000006)
2-amino-4-({1-[(carboxymethyl)-C-hydroxycarbonimidoyl]-2-[(1-hydroxy-2-methyl-3-oxo-1-phenylpropan-2-yl)sulfanyl]ethyl}-C-hydroxycarbonimidoyl)butanoic acid
C20H27N3O8S (469.15187820000006)
2-amino-4-({1-[(carboxymethyl)-C-hydroxycarbonimidoyl]-2-{[1-(2-hydroxyphenyl)-2-methyl-3-oxopropyl]sulfanyl}ethyl}-C-hydroxycarbonimidoyl)butanoic acid
C20H27N3O8S (469.15187820000006)
2-amino-4-({1-[(carboxymethyl)-C-hydroxycarbonimidoyl]-2-[(1-hydroxy-3-oxo-1-phenylbutan-2-yl)sulfanyl]ethyl}-C-hydroxycarbonimidoyl)butanoic acid
C20H27N3O8S (469.15187820000006)
2-amino-4-({1-[(carboxymethyl)-C-hydroxycarbonimidoyl]-2-{[1-(4-methoxyphenyl)-3-oxopropyl]sulfanyl}ethyl}-C-hydroxycarbonimidoyl)butanoic acid
C20H27N3O8S (469.15187820000006)
2-Amino-3-[(2-heptanoyloxy-3-hexanoyloxypropoxy)-hydroxyphosphoryl]oxypropanoic acid
C19H36NO10P (469.2076726000001)
2-Amino-3-[hydroxy-(2-octanoyloxy-3-pentanoyloxypropoxy)phosphoryl]oxypropanoic acid
C19H36NO10P (469.2076726000001)
2-Amino-3-[(3-butanoyloxy-2-nonanoyloxypropoxy)-hydroxyphosphoryl]oxypropanoic acid
C19H36NO10P (469.2076726000001)
2-Amino-3-[(2-decanoyloxy-3-propanoyloxypropoxy)-hydroxyphosphoryl]oxypropanoic acid
C19H36NO10P (469.2076726000001)
3-[(3-Acetyloxy-2-undecanoyloxypropoxy)-hydroxyphosphoryl]oxy-2-aminopropanoic acid
C19H36NO10P (469.2076726000001)
[(2S,3S,5R,6R)-2,3,5,6-tetrahydroxy-4-[(2S,3R,4S,5S)-3,4,5-trihydroxytetrahydropyran-2-yl]oxy-cyclohexyl] 2-(1H-indol-3-yl)acetate
C21H27NO11 (469.15840320000007)
methysergide
C21H27N3O2.C4H4O4 (469.2212746)
D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists D002317 - Cardiovascular Agents > D014662 - Vasoconstrictor Agents C78272 - Agent Affecting Nervous System > C47795 - CNS Stimulant
20-carboxyleukotriene E4
C23H35NO7S (469.21341200000006)
A leukotriene that is leukotriene E4 in which the terminal methyl grop has been oxidised to the corresponding carboxylic acid.
N(1),N(8)-bis(caffeoyl)spermidine
A secondary amino compound that is spermidine in which each of the primary amino groups has been mono-acylated by formal condensation with trans-caffeic acid.
2-deoxycytidine-thymidine dimer
C19H27N5O9 (469.18086919999996)
A nucleoside analogue obtained by formal cyclodimerisation of 2-deoxycytidine and thymidine.
(2s)-2-{[(3r)-3-amino-6-{[(1s)-1-carboxy-2-phenylethyl]-c-hydroxycarbonimidoyl}-1-hydroxyhexylidene]amino}-3-phenylpropanoic acid
(1s,2r,3s,4r,4ar,8as)-2,3-dihydroxy-3,4,8,8a-tetramethyl-4-[(2s)-6-oxo-2h,3h,4h-furo[2,3-c]furan-2-yl]-2,4a,5,6-tetrahydro-1h-naphthalen-1-yl pyridine-3-carboxylate
2-({3-amino-6-[(1-carboxy-2-phenylethyl)-c-hydroxycarbonimidoyl]-1-hydroxyhexylidene}amino)-3-phenylpropanoic acid
(3s,4r,5s)-3,4-dihydroxy-5-[(1s)-2-hydroxy-1-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}ethyl]-3-(1h-indol-3-ylmethyl)oxolan-2-one
C21H27NO11 (469.15840320000007)
4-[({10-amino-10-benzyl-7,9,10a-trihydroxy-3-oxo-1h,2h,5h-pyrrolo[1,2-b]isoquinolin-5-yl}(hydroxy)methylidene)amino]butanoic acid
C24H27N3O7 (469.18489120000004)
2-[3-hexanoyl-9a-methyl-2,9-dioxo-6-(prop-1-en-1-yl)furo[3,2-g]isoquinolin-7-yl]butanedioic acid
C25H27NO8 (469.17365820000003)
(1'r,2r,9r,9as,12'r)-15'-hydroxy-12'-methyl-2-(2-methylpropyl)-2,9a-dihydro-1h-2',10',16'-triazaspiro[imidazo[1,2-a]indole-9,13'-tetracyclo[10.2.2.0²,¹¹.0⁴,⁹]hexadecane]-4',6',8',10',15'-pentaene-3,3'-dione
(3s)-3-{[(2s,5s,6r)-5-amino-6-methyloxan-2-yl]oxy}-4-(1,5-dihydroxy-9,10-dioxoanthracen-2-yl)-3-methylbutanoic acid
C25H27NO8 (469.17365820000003)
3,4-dihydroxy-5-(2-hydroxy-1-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}ethyl)-3-(1h-indol-3-ylmethyl)oxolan-2-one
C21H27NO11 (469.15840320000007)
(1'r,3'r,15'r,28's)-3'-hydroxy-27'-methyl-10',13',17',25',27'-pentaazaspiro[cyclopropane-1,12'-heptacyclo[13.10.2.1³,¹⁰.0⁴,⁹.0¹⁶,²⁵.0¹⁸,²³.0¹³,²⁸]octacosane]-4',6',8',16',18',20',22'-heptaene-11',24',26'-trione
C26H23N5O4 (469.17499580000003)
4-(5,7-dihydroxy-2-methyl-4-oxochromen-8-yl)-1-methylpiperidin-3-yl 3,4-dimethoxybenzoate
C25H27NO8 (469.17365820000003)
2,3-dihydroxy-3,4,8,8a-tetramethyl-4-{6-oxo-2h,3h,4h-furo[2,3-c]furan-2-yl}-2,4a,5,6-tetrahydro-1h-naphthalen-1-yl pyridine-3-carboxylate
3'-hydroxy-27'-methyl-10',13',17',25',27'-pentaazaspiro[cyclopropane-1,12'-heptacyclo[13.10.2.1³,¹⁰.0⁴,⁹.0¹⁶,²⁵.0¹⁸,²³.0¹³,²⁸]octacosane]-4',6',8',16',18',20',22'-heptaene-11',24',26'-trione
C26H23N5O4 (469.17499580000003)
(2s)-2-[(3-amino-6-{[(1s)-1-carboxy-2-phenylethyl]-c-hydroxycarbonimidoyl}-1-hydroxyhexylidene)amino]-3-phenylpropanoic acid
(2s,3s,4r,5s,6r)-5-methoxy-6-methyl-29-oxa-1,7,17-triazaoctacyclo[12.12.2.1²,⁶.0⁷,²⁸.0⁸,¹³.0¹⁵,¹⁹.0²⁰,²⁷.0²¹,²⁶]nonacosa-8(13),9,11,14(28),15(19),17,20(27),21(26),22,24-decaene-3,4,18-triol
C27H23N3O5 (469.16376280000003)
15'-hydroxy-12'-methyl-2-(2-methylpropyl)-2,9a-dihydro-1h-2',10',16'-triazaspiro[imidazo[1,2-a]indole-9,13'-tetracyclo[10.2.2.0²,¹¹.0⁴,⁹]hexadecane]-4',6',8',10',15'-pentaene-3,3'-dione
8,17-dihydroxy-17-(2-hydroxy-4,5-dihydro-1,3-thiazol-4-yl)-9-methoxy-5,12-dimethyl-2,16-dioxabicyclo[13.3.1]nonadeca-4,10-dien-3-one
C23H35NO7S (469.21341200000006)
(2r)-2-[(9ar)-3-hexanoyl-9a-methyl-2,9-dioxo-6-[(1e)-prop-1-en-1-yl]furo[3,2-g]isoquinolin-7-yl]butanedioic acid
C25H27NO8 (469.17365820000003)
4-[6-(2,4-dihydroxy-6-methylbenzoyloxy)-4-hydroxy-5-(3-methylbut-2-en-1-yl)-1-oxo-3h-isoindol-2-yl]butanoic acid
C25H27NO8 (469.17365820000003)
(2s)-2-[(9ar)-3-hexanoyl-9a-methyl-2,9-dioxo-6-[(1e)-prop-1-en-1-yl]furo[3,2-g]isoquinolin-7-yl]butanedioic acid
C25H27NO8 (469.17365820000003)
ethyl 4-oxo-4-[(9s)-4,5,15,16-tetramethoxy-10-azatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1(17),2,4,6,13,15-hexaen-10-yl]butanoate
(1r,4z,8s,9s,10z,12s,15r,17r)-8,17-dihydroxy-17-[(4r)-2-hydroxy-4,5-dihydro-1,3-thiazol-4-yl]-9-methoxy-5,12-dimethyl-2,16-dioxabicyclo[13.3.1]nonadeca-4,10-dien-3-one
C23H35NO7S (469.21341200000006)